U2OS Cells

U2OS cells, an osteosarcoma cell line derived from a human osteosarcoma patient, play a significant role in cancer research, particularly in the study of bone cancer. U2OS cells are used extensively in cancer research, drug development, apoptosis studies, genetic research, and radiation oncology studies. The value of U2OS cells lies in their application to investigate apoptosis and drug resistance, essential for creating small molecule inhibitors and similar therapeutic agents. In the realm of clinical osteosarcoma research, the U2OS cell line is instrumental in examining biological responses to radiotherapy, thereby enriching our understanding of osteosarcoma biology. These cells are also pivotal in investigating chromatin modifications and their impact on cell biology, especially in the context of tumor formation and cancer progression. The U2OS cell line, also referred to as the OS cell line, is recognized for its in vivo tumor formation capacity when administered through subcutaneous and intramuscular injections. The tumors produced by U2OS cells are characterized as high-grade sarcomas and exhibit significant osteoid production, which is a hallmark of osteosarcoma. Additionally, these tumors showed infiltration by immune cells. U2OS therefore serves as a representative model for studying human osteosarcoma, its interactions with the human immune system and tumor immunology. One of the challenges, however, is ensuring the osteosarcoma U2OS cell line accurately reflects the tumors in vivo, given the variability in tumor formation capacity. In summary, sarcoma cell lines such as U2OS serve as a pivotal tool in understanding osteosarcoma, offering valuable insights into cancer biology, therapeutic development, and the complexities of tumor-immune system interactions, while highlighting the need for accurate in vivo tumor modeling.

SKU:BHC11100399

• SDS (E92D475A72C646E5AEE558B73DCB81C4)
• Product Sheet (E92D475A72C646E5AEE558B73DCB81C4)
• U2OS 300364-1322 Cytion CoA (PDF)
• U2OS 300364-190825 Cytion CoA (PDF)

• Receptors expressed: Insulin-like growth factor I (IGF-I), insulin-like growth factor II (IGF-I), Osteosarcoma derived growth factor (ODGF)
• Antigen expression: Blood Type A, Rh+, HLA A2, Aw30, B12, Bw35, B40(+/-)
• Isoenzymes: PGM3, 1, PGM1, 2, ES-D, 1, AK-1, 1, GLO-1, 2, G6PD, B, Phenotype Frequency Product: 0.0082
• Products: Osteosarcoma derived growth factor (ODGF)
• Karyotype: (P11-46) hypodiploid to near tetraploid, (P111-118) modal numbers 34 to 37 and 64 to 67 with abnormalities including dicentrics, breaks, rings, and pulverizations plus acrocentric subtelocentric and minute markers

• cultureMedium: DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a)
• supplements: Supplement the medium with 10% FBS
• dissociationReagent: Accutase
• subculturing: Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.
• seedingDensity: 1 x 104 cells/cm2
• fluidRenewal: 2 to 3 times per week
• freezeMedium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.